The revenue for INKmune is expected to reach an annual total of $14 mn by 2039 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
INKmune Overview
INKmune is under development for the treatment of acute myelocytic leukemia, lymphoma, chronic myelomonocytic leukemia (CMML), multiple myeloma, myelodysplastic syndrome, nasopharyngeal cancer and epithelial cancers including breast, metastatic ovarian, prostate, renal and lung cancer. It is also under development for metastatic castration-resistant prostate cancer (mCRPC). It is administered by the intravenous and intraperitoneal routes. It is a biologic delivery system that delivers the missing S1 (priming signal) to the patient’s resting NK cells.
Inmune Bio Overview
Inmune Bio is a clinical stage biotechnology company. It develops novel immunotherapies to treat the cancer. The company’s product portfolio includes INKmune, a biologic delivery system which allows delivery of essential priming signals to patients’ resting NK cells; INB03 is a protein biologic inhibitor, for the treatment of cancer; XPro1595, a protein biologic that targets soluble TNF (sTNF) in Alzheimer’s disease and NeuLiv, for the treatment of nonalcoholic steatohepatitis. It serves in the therapeutic areas of tumor cells, immune system. It offers products under Inkmune and NeuLiv brand names. The company has operations in the US. Inmune Bio is headquartered in La Jolla, California, the US.
The company reported revenues of (US Dollars) US$0.4 million for the fiscal year ended December 2022 (FY2022), compared to a revenue of US$0.2 million in FY2021. The operating loss of the company was US$26 million in FY2022, compared to an operating loss of US$29.2 million in FY2021. The net loss of the company was US$27.3 million in FY2022, compared to a net loss of US$30.3 million in FY2021.
For a complete picture of INKmune’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.
The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.